Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord DrugsBOM:538965 +1.38%67 Net Margin % is 1.39% as of Mar. 2026, which is 46% above its 10-year median of 0.95. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.93 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 962 Drug Manufacturers companies, Concord Drugs ranks worse than 62.89% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Concord Drugs's Net Income for the
three
months ended in Mar. 2026 was ₹5.3 Mil. Concord Drugs's Revenue for the
three
months ended in Mar. 2026 was ₹378.9 Mil. Therefore, Concord Drugs's net margin for the quarter that ended in Mar. 2026 was 1.39%.
The historical rank and industry rank for Concord Drugs's Net Margin % or its related term are showing as below:
BOM:538965'
s Net Margin % Range Over the Past 10 Years
Min: 0.28 Med: 0.95 Max: 6.39
Current: 1.34
BOM:538965's Net Margin % is ranked worse than 62.89% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.37
vs BOM:538965: 1.34
Concord Drugs (BOM:538965) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Concord Drugs Net Margin % Related Terms
Concord Drugs Net Margin % Historical Data
* Premium members only.
The historical data trend for Concord Drugs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Drugs (BOM:538965) has a Net Margin % of 1.39% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Concord Drugs and its competitors. This is 46% above median its historical median of 0.95. Over the past decade, Concord Drugs' Net Margin % has ranged from 0.28 to 6.39. According to the industry distribution chart, Concord Drugs ranks #605 out of 962 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Concord Drugs' Net Margin % too high?
Concord Drugs' current Net Margin % of 1.39% is 46% above median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 6.39. The Drug Manufacturers industry median Net Margin % is 5.37. Concord Drugs' value of 1.39% is 74.1% below this industry median. Based on the distribution chart, Concord Drugs ranks #605 out of 962 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Concord Drugs ranks #605 out of 962 companies for Net Margin %. This places Concord Drugs in the lower half of its industry. The industry median Net Margin % is 5.37. Concord Drugs' value of 1.39% is 74.1% below this benchmark. Historically, Concord Drugs' own Net Margin % has ranged from 0.28 to 6.39 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 5.37, Concord Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Drugs's current Net Margin % of 1.39% is 74.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Concord Drugs and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Drugs's current Net Margin % is 1.39%, which is 46% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.93, compared to a current price of ₹71.23 — trading 16.9% above its estimated fair value. The current Net Margin % is 1.39%, which is 46% above median its 10-year median of 0.95 and 74.1% below the Drug Manufacturers industry median of 5.37. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Net Margin % is 1.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Net Margin %: 1.39% (46% above median its 10-year median of 0.95)
GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
Industry Position: 74.1% below the Drug Manufacturers median (#605 of 962)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
